Palliative Operations for Unresectable Pancreatic Cancer

2016 ◽  
pp. 319-328
Author(s):  
Hishaam Ismael ◽  
Brian Badgwell
Keyword(s):  
Pancreatic Cancer ◽  
Unresectable Pancreatic Cancer

Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis

Chemotherapy ◽  
2021 ◽  
pp. 1-7
Author(s):  
Kotone Hayuka ◽  
Hiroyuki Okuyama ◽  
Akitsu Murakami ◽  
Yoshihiro Okita ◽  
Takamasa Nishiuchi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Adverse Events ◽  
Advanced Pancreatic Cancer ◽  
Progression Free Survival ◽  
Unresectable Pancreatic Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Free Survival ◽  
Common Grade ◽  
Grade 3

<b><i>Introduction:</i></b> Patients with advanced pancreatic cancer have a poor prognosis. FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) have been established as first-line treatment, but they have not been confirmed as second-line treatment after FFX. The aim of this study was to evaluate the safety and efficacy of GnP as second-line therapy after FFX in patients with unresectable pancreatic cancer. <b><i>Methods:</i></b> Twenty-five patients with unresectable pancreatic cancer were enrolled. The patients were treated with GnP after FFX between September 2015 and September 2019. Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events were evaluated. <b><i>Results:</i></b> The response rate, disease control rate, median PFS, and median OS were 12%, 96%, 5.3 months, and 15.6 months, respectively. The common grade 3 or 4 adverse events were neutropenia (76%) and anemia (16%). <b><i>Conclusions:</i></b> GnP after FOLFIRINOX is expected to be one of the second-line recommendations for patients with unresectable pancreatic cancer.

scholarly journals Palliative care consultation and aggressive care at end of life in unresectable pancreatic cancer

2019 ◽  
Vol 26 (1) ◽  
Author(s):  
C. Lees ◽  
S. Weerasinghe ◽  
N. Lamond ◽  
T. Younis ◽  
Ravi Ramjeesingh
Keyword(s):  
Pancreatic Cancer ◽  
Palliative Care ◽  
End Of Life ◽  
Potential Effect ◽  
Unresectable Pancreatic Cancer ◽  
Palliative Care Consultation ◽  
Integral Role ◽  
Care Consultation ◽  
Aggressive Care ◽  
Key Indicators

Background Palliative care (pc) consultation has been associated with less aggressive care at end of life in a number of malignancies, but the effect of the consultation timing has not yet been fully characterized. For patients with unresectable pancreatic cancer (upcc), aggressive and resource-intensive treatment at the end of life can be costly, but not necessarily of better quality. In the present study, we investigated the association, if any, between the timing of specialist pc consultation and indicators of aggressive care at end of life in patients with upcc.Methods This retrospective cohort study examined the potential effect of the timing of specialist pc consultation on key indicators of aggressive care at end of life in all patients diagnosed with upcc in Nova Scotia between 1 January 2010 and 31 December 2015. Statistical analysis included univariable and multivariable logistic regression.Results In the 365 patients identified for inclusion in the study, specialist pc consultation was found to be associated with decreased odds of experiencing an indicator of aggressive care at end of life; however, the timing of the consultation was not significant. Residency in an urban area was associated with decreased odds of experiencing an indicator of aggressive care at end of life. We observed no association between experiencing an indicator of aggressive care at end of life and consultation with medical oncology or radiation oncology.Conclusions Regardless of timing, specialist pc consultation was associated with decreased odds of experiencing an indicator of aggressive care at end of life. That finding provides further evidence to support the integral role of pc in managing patients with a life-limiting malignancy.

UNRESECTABLE PANCREATIC CANCER

1990 ◽  
Vol 83 (Supplement) ◽  
pp. 2S-83
Author(s):  
Dale M. Mosdell ◽  
Charles Kessler ◽  
Don M. Morris
Keyword(s):  
Pancreatic Cancer ◽  
Unresectable Pancreatic Cancer

A comparison of intraoperative celiac plexus block with pharmacological therapy as a treatment for pain of unresectable pancreatic cancer

2002 ◽  
Vol 9 (3) ◽  
pp. 372-375 ◽  
Author(s):  
Masaki Okuyama ◽  
Takashi Shibata ◽  
Tetsushi Morita ◽  
Masashi Kitada ◽  
Yasuo Tukahara ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Pharmacological Therapy ◽  
Celiac Plexus ◽  
Celiac Plexus Block ◽  
Unresectable Pancreatic Cancer ◽  
Plexus Block

Prognostic Value of Altered N-Glycosylation of Circulating Glycoproteins in Patients With Unresectable Pancreatic Cancer Treated With Gemcitabine

Pancreas ◽  
2015 ◽  
Vol 44 (4) ◽  
pp. 551-556 ◽  
Author(s):  
Koji Miyahara ◽  
Kazuhiro Nouso ◽  
Yuki Morimoto ◽  
Hideaki Kinugasa ◽  
Hironari Kato ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Value ◽  
Unresectable Pancreatic Cancer

scholarly journals Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer

2017 ◽  
Vol 56 (12) ◽  
pp. 1746-1753 ◽  
Author(s):  
Joseph J. Park ◽  
Carla Hajj ◽  
Marsha Reyngold ◽  
Weiji Shi ◽  
Zhigang Zhang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Unresectable Pancreatic Cancer ◽  
Stereotactic Body Radiation ◽  
Intensity Modulated
Sign in / Sign up

Export Citation Format

Share Document